Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics.

about

Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics.

Item

http://www.wikidata.org/entity/Q47243379

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Resistance to receptor-blockin ...... for HER3-homing nanobiologics.

@en

Resistance to receptor-blockin ...... for HER3-homing nanobiologics.

@nl

type

Item

label

Resistance to receptor-blockin ...... for HER3-homing nanobiologics.

@en

Resistance to receptor-blockin ...... for HER3-homing nanobiologics.

@nl

prefLabel

Resistance to receptor-blockin ...... for HER3-homing nanobiologics.

@en

Resistance to receptor-blockin ...... for HER3-homing nanobiologics.

@nl

P1476

Resistance to receptor-blockin ...... for HER3-homing nanobiologics.

@en

P2093

Alice Chung

http://www.w3.org/2001/XMLSchema#string

Altan Rentsendorj

http://www.w3.org/2001/XMLSchema#string

Anjali Jain

http://www.w3.org/2001/XMLSchema#string

Armando Giuliano

http://www.w3.org/2001/XMLSchema#string

Beth Y Karlan

http://www.w3.org/2001/XMLSchema#string

Bingchen Han

http://www.w3.org/2001/XMLSchema#string

David Chu

http://www.w3.org/2001/XMLSchema#string

Dustin Srinivas

http://www.w3.org/2001/XMLSchema#string

Felix Alonso-Valenteen

http://www.w3.org/2001/XMLSchema#string

Hasmik Agadjanian

http://www.w3.org/2001/XMLSchema#string

P2860

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models

The deaf and the dumb: the biology of ErbB-2 and ErbB-3

HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer

Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

Proteomics. Tissue-based map of the human proteome

P304

127-138

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JCONREL.2017.12.024

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

271

http://www.w3.org/2001/XMLSchema#string

P50

Harry B. Gray

Ravinder Abrol

P577

2017-12-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29288681

http://www.w3.org/2001/XMLSchema#string

P932

5807213

http://www.w3.org/2001/XMLSchema#string